CeriBell (NASDAQ:CBLL) VP Sells $111,120.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $20.00, for a total value of $111,120.00. Following the completion of the transaction, the vice president owned 18,900 shares of the company’s stock, valued at approximately $378,000. This represents a 22.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Foehr also recently made the following trade(s):

• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total transaction of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Up 4.2%

Shares of NASDAQ CBLL opened at $20.15 on Friday. The firm’s 50-day moving average is $21.17 and its two-hundred day moving average is $15.68. The company has a market capitalization of $747.57 million, a PE ratio of -13.34 and a beta of 1.03. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CBLL shares. Canaccord Genuity Group boosted their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Raymond James Financial began coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CBLL. Ameritas Investment Partners Inc. boosted its holdings in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after acquiring an additional 1,256 shares during the last quarter. CWM LLC lifted its stake in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period. Larson Financial Group LLC increased its position in CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after purchasing an additional 2,680 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the third quarter valued at approximately $33,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.